May Health Raises $25 Million in Series B Funding to Advance Development for Ovarian Rebalancing Therapy
Summary
- Bpifrance and Trill Impact Ventures co-led the round, joining founding investor Sofinnova Partners, to support the companys pivotal REBALANCE study evaluating Ovarian Rebalancing in women with infertility caused by PCOSPARIS, May 13, 2024--(BUSINESS WIRE)--May Health, a clinical-stage medical device company dedicated to helping those living with the endocrine disorder polycystic ovary syndrome (PCOS), today announced it has closed a $25 million Series B financing round, co-led by Bpifrance and Trill Impact with participation from founding investor Sofinnova Partners, as well as Avestria Ventures and Kidron Capital Assets LP. "We are thankful to Bpifrance and Trill Impact for co-leading this financing round, together with our founding investor Sofinnova Partners, and to our deep bench of supporters and advisors for their confidence in our team and growth strategy. We are eager to continue building on the positive results of our previous clinical studies as well as this financing milestone as we work to become a leader in global womens health and PCOS-related infertility. Trill Impact is excited to collaborate with the May Health team and its strong shareholders to bring their innovative product to women who have suffered from a lack of treatment options for too long. ""For years, women with PCOS who struggle with infertility have sought alternative treatment options that go beyond IVF and laparoscopic ovarian drilling," said Dr. Robert Auerbach, OBGYN, chairman of the May Health board.